Sumitomo Mitsui Trust Holdings Inc. Has $103.59 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Sumitomo Mitsui Trust Holdings Inc. increased its position in Agilent Technologies, Inc. (NYSE:A) by 0.8% during the first quarter, Holdings Channel reports. The firm owned 711,895 shares of the medical research company’s stock after buying an additional 5,716 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Agilent Technologies were worth $103,588,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies in the 4th quarter valued at about $26,000. MV Capital Management Inc. raised its holdings in Agilent Technologies by 120.7% in the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 105 shares during the period. VisionPoint Advisory Group LLC bought a new position in Agilent Technologies in the 4th quarter valued at about $29,000. Rise Advisors LLC raised its holdings in Agilent Technologies by 527.8% in the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 190 shares during the period. Finally, Baystate Wealth Management LLC raised its holdings in Agilent Technologies by 107.3% in the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 133 shares during the period.

Analyst Ratings Changes

A has been the topic of several research analyst reports. Wolfe Research cut shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. Barclays lowered their price target on shares of Agilent Technologies from $135.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Stifel Nicolaus lowered their price target on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a report on Thursday, May 30th. Finally, Oppenheimer increased their price target on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $137.13.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the sale, the chief executive officer now owns 25,185 shares in the company, valued at $3,274,050. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the transaction, the senior vice president now owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the transaction, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The disclosure for this sale can be found here.

Agilent Technologies Stock Performance

NYSE A opened at $126.13 on Thursday. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $36.80 billion, a price-to-earnings ratio of 29.82, a P/E/G ratio of 4.40 and a beta of 1.05. The firm’s 50 day simple moving average is $139.17 and its 200 day simple moving average is $138.35. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.03. The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The firm’s revenue for the quarter was down 8.4% on a year-over-year basis. During the same quarter last year, the business posted $1.27 EPS. As a group, research analysts expect that Agilent Technologies, Inc. will post 5.25 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be given a dividend of $0.236 per share. The ex-dividend date is Tuesday, July 2nd. This represents a $0.94 annualized dividend and a dividend yield of 0.75%. Agilent Technologies’s dividend payout ratio is 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.